184 related articles for article (PubMed ID: 21306281)
1. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis.
Thöne J; Gold R
Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):365-70. PubMed ID: 21306281
[TBL] [Abstract][Full Text] [Related]
2. Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.
Tselis A
Curr Opin Investig Drugs; 2010 May; 11(5):577-85. PubMed ID: 20419604
[TBL] [Abstract][Full Text] [Related]
3. Laquinimod in multiple sclerosis.
Giacomini PS; Bar-Or A
Clin Immunol; 2012 Jan; 142(1):38-43. PubMed ID: 21450529
[TBL] [Abstract][Full Text] [Related]
4. Laquinimod for multiple sclerosis.
He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
[TBL] [Abstract][Full Text] [Related]
5. Review of laquinimod and its therapeutic potential in multiple sclerosis.
Thöne J; Gold R
Expert Opin Pharmacother; 2013 Dec; 14(18):2545-52. PubMed ID: 24215556
[TBL] [Abstract][Full Text] [Related]
6. Oral laquinimod therapy in relapsing multiple sclerosis.
Preiningerova J
Expert Opin Investig Drugs; 2009 Jul; 18(7):985-9. PubMed ID: 19527103
[TBL] [Abstract][Full Text] [Related]
7. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Polman C; Barkhof F; Sandberg-Wollheim M; Linde A; Nordle O; Nederman T;
Neurology; 2005 Mar; 64(6):987-91. PubMed ID: 15781813
[TBL] [Abstract][Full Text] [Related]
8. Emerging oral drugs for relapsing-remitting multiple sclerosis.
Gasperini C; Ruggieri S
Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
[TBL] [Abstract][Full Text] [Related]
9. Oral treatment for multiple sclerosis.
Killestein J; Rudick RA; Polman CH
Lancet Neurol; 2011 Nov; 10(11):1026-34. PubMed ID: 22014437
[TBL] [Abstract][Full Text] [Related]
10. Oral laquinimod treatment in multiple sclerosis.
Fernández O
Neurologia; 2011 Mar; 26(2):111-7. PubMed ID: 21163185
[TBL] [Abstract][Full Text] [Related]
11. Laquinimod in the treatment of relapsing remitting multiple sclerosis.
Hainke U; Thomas K; Ziemssen T
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):701-9. PubMed ID: 27089834
[TBL] [Abstract][Full Text] [Related]
12. Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Comi G; Jeffery D; Kappos L; Montalban X; Boyko A; Rocca MA; Filippi M;
N Engl J Med; 2012 Mar; 366(11):1000-9. PubMed ID: 22417253
[TBL] [Abstract][Full Text] [Related]
13. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Jolivel V; Luessi F; Masri J; Kraus SH; Hubo M; Poisa-Beiro L; Klebow S; Paterka M; Yogev N; Tumani H; Furlan R; Siffrin V; Jonuleit H; Zipp F; Waisman A
Brain; 2013 Apr; 136(Pt 4):1048-66. PubMed ID: 23518712
[TBL] [Abstract][Full Text] [Related]
14. Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.
Constantinescu SE; Constantinescu CS
Expert Rev Clin Pharmacol; 2016; 9(1):49-57. PubMed ID: 26536299
[TBL] [Abstract][Full Text] [Related]
15. [Current treatment of multiple sclerosis].
Csépány T
Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod for relapsing multiple sclerosis: an update.
Horga A; Castilló J; Montalban X
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[TBL] [Abstract][Full Text] [Related]
17. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Comi G; Pulizzi A; Rovaris M; Abramsky O; Arbizu T; Boiko A; Gold R; Havrdova E; Komoly S; Selmaj K; Sharrack B; Filippi M;
Lancet; 2008 Jun; 371(9630):2085-92. PubMed ID: 18572078
[TBL] [Abstract][Full Text] [Related]
18. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
19. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.
Brück W; Zamvil SS
Expert Rev Clin Pharmacol; 2012 May; 5(3):245-56. PubMed ID: 22697588
[TBL] [Abstract][Full Text] [Related]
20. New oral drugs for multiple sclerosis.
Gasperini C; Ruggieri S
Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
